Expanding Diagnostic Offerings DxTerity Diagnostics has recently launched innovative tests such as the IFN-1 Test for systemic lupus erythematosus and at-home COVID-19 testing solutions, indicating strong growth in diagnostic product development and market reach. This presents opportunities to collaborate with healthcare providers and insurance companies to expand test adoption.

Strategic Partnerships The company's collaboration with Amazon to distribute SARS-CoV-2 tests highlights an openness to scalable distribution channels and e-commerce integration. Leveraging such partnerships can help extend sales channels to a broader consumer base, including small businesses and individual consumers seeking at-home testing.

Focus on Autoimmune and Infectious Disease Markets DxTerity's emphasis on autoimmune conditions like lupus and infectious diseases via COVID-19 testing positions it well to tap into the growing demand for specialized diagnostics in these high-need healthcare segments. Engaging with immunology clinics and infectious disease specialists could yield new customer opportunities.

Technology Integration With a tech stack that includes Salesforce, Python, and MySQL, DxTerity demonstrates a capability for robust data management and customer relationship management. This can be utilized to personalize outreach and streamline sales processes, especially when targeting healthcare institutions and diagnostic labs.

Market Penetration Challenges Given the company's current revenue range and small team size, there is a significant opportunity in forming strategic alliances and distribution agreements to accelerate sales growth. Targeting mid-sized biotechnology firms and healthcare providers eager to expand or diversify their diagnostic offerings could be beneficial.